Table 1 Demographics and clinical data
Characteristics | Overall (n = 54) | Surgically-treated type A AD with residual tear (n = 35) | Medically-treated type B AD (n = 19) | P-value |
|---|---|---|---|---|
Age [years] | 66 ± 11 | 68 ± 11 | 64 ± 10 | 0.174 |
Sex [male] | 44 (81%) | 27 (77%) | 17 (89%) | 0.265 |
BSA [m2] | 1.9 ± 0.2 | 1.9 ± 0.2 | 1.9 ± 0.2 | 0.701 |
SBP [mmHg] | 138 ± 20 | 140 ± 21 | 134 ± 20 | 0.278 |
DBP [mmHg] | 79 ± 13 | 76 ± 12 | 84 ± 15 | 0.128 |
Stroke volume [mL] | 55 ± 19 | 53 ± 19 | 57 ± 20 | 0.488 |
Active smoker | 10 (19%) | 6 (18%) | 4 (21%) | 0.800 |
Hypertension | 34 (65%) | 21 (64%) | 13 (68%) | 0.727 |
Diabetes mellitus | 5 (10%) | 3 (9%) | 2 (10%) | 0.866 |
Dyslipidaemia | 12 (23%) | 7 (21%) | 5 (26%) | 0.674 |
Mechanical prosthetic aortic valve | 10 (19%) | 9 (26%) | 1 (5%) | 0.058 |
Anticoagulation therapy | 24 (44%) | 18 (51%) | 6 (32%) | 0.163 |
Antiplatelet therapy | 14 (26%) | 12 (35%) | 2 (10%) | 0.051 |
Statin therapy | 22 (44%) | 14 (45%) | 8 (42%) | 0.833 |
Heart rate [bpm] | 63 ± 10 | 65 ± 10 | 61 ± 9 | 0.330 |
Follow-up duration between baseline and final CTAs [months] | 35 ± 11 | 33 ± 11 | 34 ± 12 | 0.878 |
Time between acute AD and 4D flow [months] | 78 ± 81 | 95 ± 92 | 47 ± 43 | 0.099 |
Aortic growth rate [mm/year] | 1.8 ± 1.6 | 1.7 ± 1.6 | 1.9 ± 1.6 | 0.550 |